Infectious disease environment
Infectious disease environment is a barrier to human progress within the environmental factors. The evidence for it, and the methods proposed to address it, follow.
Infectious disease harms health and schooling.
Evidence
- Malaria. WHO's World Malaria Report 2025 estimated 282 million cases and 610,000 deaths in 2024, up from a revised 273 million cases in 2023. About 95% of deaths occurred in the WHO African Region, mostly among children under 5. Most victims are young children. So malaria removes potential future contributors, including possible pioneers, before any ability can develop.
- Parasites and schooling. The Rockefeller Sanitary Commission found that 40% of school-aged children in the American South had hookworm. Bleakley (2007) found that after treatment, areas with more infection saw larger gains in enrollment, attendance, literacy, and later income. An independent replication (Roodman, 2018) questioned whether these benefits are robust.
- Tuberculosis. WHO estimates that 10.7 million people fell ill with tuberculosis (TB) in 2024, including 1.2 million children. WHO estimates that 1.23 million died, including 150,000 people with HIV. This makes TB the world's leading cause of death from a single infectious agent. About half of people treated for TB and their households face costs above 20% of household income. An estimated 0.97 million new cases in 2024 were attributable to undernutrition. These are modelled estimates (WHO, 2026).
- Malaria and schooling. This study used mid-20th-century malaria eradication campaigns in Sri Lanka and Paraguay. It compared women born before and after eradication in more and less affected regions. A 10 percentage point fall in malaria incidence raised completed schooling by about 0.1 years and literacy by about 1 percentage point. In Sri Lanka, eradication accounted for roughly half of the rise in completed education in the period studied. The Paraguay results were not significant with the most conservative statistical tests, and the data cover only women (Lucas, 2010).
- Infection before birth. Almond (2006) used the 1918 influenza pandemic, which infected about a third of US women of childbearing age. He also used 1960 to 1980 census data. He found that people exposed in the womb had less education, more disability, and lower income as adults. He estimated that sons of infected mothers were about 9% less likely to finish high school and earned 5 to 6% less. Later work found that fathers of the 1919 birth cohort were of lower status, which questions the original estimates. Still, a study using city-level pandemic intensity found lower high school graduation (Almond, 2006).
Why it matters: A place full of disease can look like a lack of effort or ability. Remove the disease and the "deficit" often shrinks.
What can be done
Actions rated on the strength-rating scale (A strong and replicated, B solid but limited, C weak or debated, D contested or failed), applied to the specific claim made.
- Insecticide-treated bed nets (A). A Cochrane review of 23 trials found that nets reduced child deaths from all causes by 17% compared with no nets (rate ratio 0.83, 5 trials, 200,833 participants). The review found this saved 5.6 lives per 1,000 children protected each year. It also found nets nearly halved uncomplicated falciparum malaria (Pryce et al., 2018). The trials ran from 1987 to 2001, before widespread pyrethroid resistance. For nets in pregnancy see "Low birth weight and prenatal health" in the biological factors. For newer dual-ingredient nets see the proposed methods below.
- Seasonal malaria chemoprevention for children (A for malaria cases, B for severe malaria). WHO recommended monthly antimalarial drugs during the transmission season in 2012. The drugs reach more than 30 million Sahelian children a year. In 12 randomized studies, they reduced uncomplicated malaria by 73% (rate ratio 0.27 in both under-5s and older children). They also reduced severe malaria in children under 10 (risk ratio 0.53). But they showed no evidence of lower mortality (Thwing et al., 2024). The evidence comes from areas where the drugs still worked.
- Routine childhood vaccination (A for rotavirus vaccines, C for the global estimate). A Cochrane review of 60 trials with 228,233 participants looked at rotavirus vaccines. The review found that in the first year the vaccines prevented 93% of severe rotavirus diarrhoea in low-mortality countries and 58% in high-mortality countries (Rotarix). It found no increased risk of serious adverse events (Bergman et al., 2021). A WHO-funded modelling study estimated that vaccination against 14 pathogens since 1974 averted 154 million deaths. The same study estimated that this accounted for 40% of the fall in global infant mortality (Shattock et al., 2024). The global figure depends on model assumptions.
- Pooled international financing of vaccines for poor countries, Gavi (B). One study used differences in when Gavi began funding each vaccine in each country. It found that Gavi support raised coverage by 2 to 5 percentage points across all vaccines and by 10 to 20 points for newer vaccines. The study found Gavi support also reduced child mortality from related causes by 1 per 1,000 live births. The authors estimate that this saved about 1.5 million lives at about $9,000 per life (Shastry and Tortorice, 2025). A reanalysis with newer estimators kept the direction but found smaller effects. The reanalysis found about 0.25 to 0.63 deaths per 1,000 live births, depending on the estimator (Hsieh, 2026). An earlier difference-in-differences study of 51 countries found that Gavi support raised DPT coverage by 12.02 percentage points. The same study found it reduced under-five deaths by 12.23 per 1,000 live births (Jaupart, Dipple, and Dercon, 2019).
- Mass azithromycin for young children in high-mortality areas (B). The MORDOR trial covered 1,533 communities in Malawi, Niger, and Tanzania. In this trial, four twice-yearly doses cut child mortality by 13.5% overall, by 18.1% in Niger, and by 24.9% in infants aged 1 to 5 months. Effects in Malawi and Tanzania were not significant (Keenan et al., 2018). In Niger, communities recently given azithromycin had 2.18 times more macrolide resistance genes in the gut. WHO issued only a conditional recommendation because of resistance concerns (Arzika et al., 2024).
- Oral rehydration solution and zinc for childhood diarrhoea (A for the reduced osmolarity solution, B for zinc, C for the mortality estimate). A systematic review drew on 157 papers about oral rehydration solution. It estimated that the solution may prevent 93% of diarrhoea deaths in children under 5. The review used a set of review rules to combine evidence of mixed quality (Munos, Walker, and Black, 2010). In children admitted to hospital, a reduced osmolarity solution led to fewer unscheduled intravenous infusions than the older standard solution (odds ratio 0.59, 8 trials) (Hahn, Kim, and Garner, 2002). A Cochrane review of 33 trials with 10,841 children found that zinc probably reduced the number of children over 6 months whose diarrhoea lasted to day 7 (risk ratio 0.73). The same review showed no benefit under 6 months and found more vomiting (Lazzerini and Wanzira, 2016).
- Not shown to add benefit: indoor residual spraying with pyrethroid-like insecticides where nets are used (B). Some spraying uses insecticides that work like those on nets. Adding this kind of spraying did not change malaria incidence (rate ratio 1.07, 2 trials) or parasite prevalence (Pryce, Medley, and Choi, 2022). Spraying with insecticides that act differently reduced parasite prevalence (risk ratio 0.61, high certainty). But the effect on incidence was uncertain and absent in two studies.
- Mixed: mass drug administration for malaria (B). A Cochrane review of 13 studies looked at giving antimalarial drugs to whole communities. In very low to low transmission areas, the review found this cut falciparum parasite prevalence one to three months later (risk ratio 0.25, 7 studies, low certainty). But no effect was shown after four months. In moderate to high transmission areas, the review found no important effect on prevalence within six months. No study showed that transmission was interrupted (Shah et al., 2021). For seasonal drugs given to children see the chemoprevention entry above.
Proposed and experimental methods
Methods that are proposed, under trial, approved in some places, or tried and then failed. Each shows a stage label and an evidence rating. A stage label shows how far a method has progressed, not whether it works. The stage labels are explained on the environmental factor page.
- Dual active ingredient bed nets (Approved but not scaled, A). Nets that add chlorfenapyr, an insecticide that works in a different way, to a pyrethroid, because mosquitoes now resist pyrethroids. In a four-arm cluster randomized trial in Tanzania, malaria infection at 24 months was 25.6% with chlorfenapyr nets versus 45.8% with standard nets (adjusted odds ratio 0.45) (Mosha et al., 2022). In Benin, malaria incidence was 0.56 versus 1.03 cases per child-year (hazard ratio 0.54) (Accrombessi et al., 2023). WHO issued a strong recommendation for these nets in 2023 (WHO, 2023). Net use fell to 41% to 61% by 24 months. The Tanzania authors call for resistance management before scale-up.
- Malaria vaccines R21 and RTS,S (Approved but not scaled, B). A phase 3 trial of R21/Matrix-M included 4,878 African children. The vaccine had 75% efficacy against clinical malaria over 12 months at seasonal sites and 68% at year-round sites (Datoo et al., 2024). RTS,S was introduced through routine immunization in Ghana, Kenya, and Malawi, with randomized timing across 158 areas. In that rollout, eligible children had 32% fewer hospital admissions with severe malaria and 9% lower all-cause mortality. The earlier safety signals did not appear (Asante et al., 2024). Third-dose coverage was 62% to 66%.
- Wolbachia-infected mosquitoes (Approved but not scaled, contested, B). Releasing Aedes mosquitoes that carry the Wolbachia bacterium, which blocks dengue transmission. In a cluster randomized trial in Yogyakarta, Indonesia, dengue was 77.1% lower and dengue hospitalization 86.2% lower in release areas (Utarini et al., 2021). In Campo Grande, Brazil, stable establishment was associated with 63.2% less dengue (de Morais Batista et al., 2026). But in Rio de Janeiro only 32% of local mosquitoes carried Wolbachia, and Wolbachia failed to recover after insecticide use (Pavan et al., 2025). One review calls for a pause and independent re-evaluation. The review cites loss of Wolbachia and outbreaks in release zones (Marinotti et al., 2026).
- Spatial repellents (Large trial, contested, C). Devices that release a repellent, here transfluthrin, into the air of a home. In western Kenya, where net coverage was high, the devices cut first-time malaria infection by 33.4% (Ochomo et al., 2025). But a sister trial in Mali found no effect (protective efficacy -3.10%). That result is in a report not yet peer-reviewed (Sagara et al., 2025).
- Reversed: Target Malaria in Burkina Faso (Failed or reversed, B). Target Malaria is developing genetically modified mosquitoes to suppress malaria vectors, with gene drive as the long-term goal. In August 2025 Burkina Faso's authorities ordered all of Target Malaria's activities in the country stopped. The order came days after a small release of non-gene drive modified male mosquitoes. The project gave no reason in its statement (Target Malaria, 2025).
Sources cited on this page
- WHO: Burden of disease from unsafe water, sanitation and hygiene, 2019 update (2023) B Moderate
- Bleakley, H. (2007). Disease and development: evidence from hookworm eradication in the American South. Quarterly Journal of Economics, 122(1), 73-117. Oxford Academic C Limited
- Roodman, D. (2018). The impacts of hookworm eradication in the American South: a replication study of Bleakley (2007). International Journal for Re-Views in Empirical Economics, 2, 1-45. JCR-Econ B Moderate
- Almond, D. (2006). Is the 1918 influenza pandemic over? Long-term effects of in utero influenza exposure in the post-1940 U.S. population. Journal of Political Economy, 114(4), 672-712. DOI C Limited: for lower schooling, D for the size of the income and disability effects
- Lucas, A. M. (2010). Malaria eradication and educational attainment: Evidence from Paraguay and Sri Lanka. American Economic Journal: Applied Economics, 2(2), 46-71. DOI B Moderate
- Ma, L., Graham, D. J., & Stettler, M. E. J. (2021). Has the ultra low emission zone in London improved air quality? Environmental Research Letters, 16, 124001. link B Moderate
- Accrombessi, M., Cook, J., Dangbenon, E., Yovogan, B., Akpovi, H., Sovi, A., et al. (2023). Efficacy of pyriproxyfen-pyrethroid long-lasting insecticidal nets (LLINs) and chlorfenapyr-pyrethroid LLINs compared with pyrethroid-only LLINs for malaria control in Benin: A cluster-randomised, superiority trial. Lancet, 401(10375), 435-446. link A Strong
- Asante, K. P., Mathanga, D. P., Milligan, P., Akech, S., Oduro, A., Mwapasa, V., et al. (2024). Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: Evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. Lancet, 403(10437), 1660-1670. link B Moderate
- Datoo, M. S., Dicko, A., Tinto, H., Ouédraogo, J.-B., Hamaluba, M., Olotu, A., et al. (2024). Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: A multicentre, double-blind, randomised, phase 3 trial. Lancet, 403(10426), 533-544. link B Moderate
- de Morais Batista, F., Carcamo, P. M., Nelson, E., da Silva Neto, A. B., Tsuha, D. H., Lahdo, V., et al. (2026). The impact of large-scale release of Wolbachia mosquitoes on dengue incidence in Campo Grande, Brazil: An ecological study. Lancet Regional Health: Americas, 54, 101327. link C Limited
- Marinotti, O., Paldi, N., & Gorla, D. (2026). Wolbachia releases for dengue control: Why the evidence supports a pause and independent re-evaluation. Infectious Diseases, 58(10), 991-1001. link C Limited
- Mosha, J. F., Kulkarni, M. A., Lukole, E., Matowo, N. S., Pitt, C., Messenger, L. A., et al. (2022). Effectiveness and cost-effectiveness against malaria of three types of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in Tanzania: A four-arm, cluster-randomised trial. Lancet, 399(10331), 1227-1241. link A Strong
- Ochomo, E. O., Gimnig, J. E., Awori, Q., Abong'o, B., Oria, P., Ashitiba, N. K., et al. (2025). Effect of a spatial repellent on malaria incidence in an area of western Kenya characterised by high malaria transmission, insecticide resistance, and universal coverage of insecticide treated nets (part of the AEGIS Consortium): A cluster-randomised, controlled trial. Lancet, 405(10473), 147-156. link B Moderate
- Pavan, M. G., Gnonhoue, F. J., Corrêa-Antônio, J., Padilha, K. P., Garcia, G. A., de Oliveira, F., et al. (2025). The long-term persistence of the wMel strain in Rio de Janeiro is threatened by poor integrated vector management and bacterium fitness cost on Aedes aegypti. PLoS Neglected Tropical Diseases, 19(7), e0013372. link C Limited
- Sagara, I., Dicko, A., Thera, I., Coulibaly, M., et al. (2025). Effect of a spatial repellent on malaria incidence in Mali: A cluster-randomized, controlled trial [Preprint]. medRxiv. link C Limited
- Utarini, A., Indriani, C., Ahmad, R. A., Tantowijoyo, W., Arguni, E., Ansari, M. R., et al. (2021). Efficacy of Wolbachia-infected mosquito deployments for the control of dengue. New England Journal of Medicine, 384(23), 2177-2186. link B Moderate
- Roodman, D. (2024). The arrival of fast internet and employment in Africa: Comment (I4R Discussion Paper No. 148). Institute for Replication. link B Moderate
- South, E. C., Hohl, B. C., Kondo, M. C., MacDonald, J. M., & Branas, C. C. (2018). Effect of greening vacant land on mental health of community-dwelling adults: A cluster randomized trial. JAMA Network Open, 1(3), e180298. link B Moderate
- Arzika, A. M., Abdou, A., Maliki, R., Beido, N., Kadri, B., Harouna, A. N., et al. (2024). Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR). PLOS Medicine, 21(5), e1004386. link B Moderate
- Bergman, H., Henschke, N., Hungerford, D., Pitan, F., Ndwandwe, D., Cunliffe, N., & Soares-Weiser, K. (2021). Vaccines for preventing rotavirus diarrhoea: Vaccines in use. Cochrane Database of Systematic Reviews, 2021(11), CD008521. link A Strong
- Keenan, J. D., Bailey, R. L., West, S. K., Arzika, A. M., Hart, J., Weaver, J., et al. (2018). Azithromycin to reduce childhood mortality in sub-Saharan Africa. New England Journal of Medicine, 378(17), 1583-1592. link B Moderate
- Pryce, J., Medley, N., & Choi, L. (2022). Indoor residual spraying for preventing malaria in communities using insecticide-treated nets. Cochrane Database of Systematic Reviews, 2022(1), CD012688. link B Moderate
- Pryce, J., Richardson, M., & Lengeler, C. (2018). Insecticide-treated nets for preventing malaria. Cochrane Database of Systematic Reviews, 2018(11), CD000363. link A Strong
- Shattock, A. J., Johnson, H. C., Sim, S. Y., Carter, A., Lambach, P., Hutubessy, R. C. W., et al. (2024). Contribution of vaccination to improved survival and health: Modelling 50 years of the Expanded Programme on Immunization. The Lancet, 403(10441), 2307-2316. link C Limited
- Thwing, J., Williamson, J., Cavros, I., & Gutman, J. R. (2024). Systematic review and meta-analysis of seasonal malaria chemoprevention. The American Journal of Tropical Medicine and Hygiene, 110(1), 20-31. link A Strong
- Bleakley, H. (2010). Malaria eradication in the Americas: A retrospective analysis of childhood exposure. American Economic Journal: Applied Economics, 2(2), 1-45. link B Moderate
- Hahn, S., Kim, S., & Garner, P. (2002). Reduced osmolarity oral rehydration solution for treating dehydration caused by acute diarrhoea in children. Cochrane Database of Systematic Reviews, 2002(1), CD002847. link A Strong
- Hsieh, M. H. (2026). Stacked triple differences (arXiv:2604.22982) [Preprint]. arXiv. link B Moderate
- Jaupart, P., Dipple, L., & Dercon, S. (2019). Has Gavi lived up to its promise? Quasi-experimental evidence on country immunisation rates and child mortality. BMJ Global Health, 4(6), e001789. link B Moderate
- Lazzerini, M., & Wanzira, H. (2016). Oral zinc for treating diarrhoea in children. Cochrane Database of Systematic Reviews, 2016(12), CD005436. link B Moderate
- Munos, M. K., Walker, C. L. F., & Black, R. E. (2010). The effect of oral rehydration solution and recommended home fluids on diarrhoea mortality. International Journal of Epidemiology, 39(Suppl. 1), i75-i87. link C Limited
- Shah, M. P., Hwang, J., Choi, L., Lindblade, K. A., Kachur, S. P., & Desai, M. (2021). Mass drug administration for malaria. Cochrane Database of Systematic Reviews, 2021(9), CD008846. link B Moderate
- Shastry, G. K., & Tortorice, D. L. (2025). Effective health aid: Evidence from Gavi's vaccine program. American Economic Journal: Economic Policy, 17(1), 540-574. link B Moderate
Every source for this factor is listed on the environmental factor page.